Advisors Preferred’s Legend Biotech LEGN Stock Holding History

Advisors Preferred’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-37,584	Closed	-$808K	–	254
2025 Q4	$808K	Buy	+37,584	New	+$1.08M	0.13%	117

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FBIL

First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Advisors Preferred's LEGN Position: Q1 2026 in Review

Advisors Preferred sold out of Legend Biotech (LEGN) in Q1 2026, closing a stake of 37,584 shares — an estimated $808K sold.

Advisors Preferred first reported a position in LEGN in Q4 2025 and held it in 1 quarter. The position peaked at $808K in Q4 2025. 190 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

Advisors Preferred reported no remaining Legend Biotech position as of Q1 2026 after selling out during the quarter.
Advisors Preferred sold 37,584 Legend Biotech shares in Q1 2026, an estimated $808K.
Advisors Preferred first reported a position in Legend Biotech in Q4 2025 and held it in 1 quarter.
Advisors Preferred's Legend Biotech position peaked at $808K in Q4 2025.
190 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Advisors Preferred's 13F filing for Q1 2026, filed 5 May 2026.